Agendia’s BluePrint Molecular Subtyping Assay Highlighted at the 32nd Annual Miami Breast Cancer Conference
Results of the NBRST Trial Using Agendia’s BluePrint 80-Gene Molecular Read More
Agendia Receives New FDA Clearance for MammaPrint FFPE Breast Cancer Test
FDA Decision Covers Use of MammaPrint in FFPE for the 70-Gene Read More
Agendia’s MammaPrint and BluePrint Tests to Be Highlighted at San Antonio Breast Cancer Symposium
Expert Symposium Panel Will Offer Insights Into How Functional Molecular Subtypes Read More
Agendia Breast Cancer Test for Molecular Subtyping Improves Match of Therapy to Patient, Study Finds
IRVINE, CA and AMSTERDAM – New data from an ongoing Read More
Agendia Board of Directors Appoints Jan Egberts, M.D., as CEO
IRVINE, CA and AMSTERDAM – Agendia, Inc., a leading molecular Read More
Agendia Test for Molecular Subtyping of Breast Cancer Is a Better Guide to Pre-Surgical Treatment, Study Finds
IRVINE, CA and AMSTERDAM – In findings that could eventually Read More
Agendia Announces Study Showing Molecular Subtyping Can Improve Breast Cancer Treatment
IRVINE, CA and AMSTERDAM – In findings that may eventually Read More
Agendia Co-Founder and CSO Develops Method to Identify Women Who Will Benefit from Tamoxifen Therapy for Breast Cancer
IRVINE, CA and AMSTERDAM, July 31, 2014 – Innovative research Read More
Agendia and CBLPath Announce Agreement to Assist Physicians in Diagnostic Assessment of Breast Cancer
IRVINE, CA, AMSTERDAM and Rye Brook, N.Y., July 16, 2014 Read More
Value of Breast Cancer Molecular Subtyping Documented by Independent Study Comparing Genomic Tests at ASCO 2014 Meeting
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, June 10, 2014 – Read More
